EUVIMEDEUVIMED entdecken
Crossref

Immune‐Hot tumor features associated with recurrence in early‐stage ovarian clear cell carcinoma

Ruby Yun-Ju Huang, Kuan-Ju Huang iD, Ko-Chen Chen, Sheng-Mou Hsiao, Tuan Zea Tan, Chin-Jui Wu, Ching Hsu, Wen-Chun Chang, Chen-Yu Pan, Bor-Ching Sheu, Lin-Hung Wei

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Ruby Yun-Ju Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Carcinoma, Adenocarcinoma, Clear Cell. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian clear cell carcinoma (OCCC) is a distinct histotype of ovarian cancer, which usually presages a worse prognosis upon recurrence. Identifying patients at risk for relapse is an unmet need to improve outcomes. A retrospective cohort analysis of 195 early‐stage OCCC patients diagnosed between January 2011 and December 2019 at National Taiwan University Hospital was conducted to identify prognostic factors for recurrence, progression‐free survival (PFS) and overall survival (OS). Molecular profiling of tumors was performed in a case‐controlled cohort matched for adjuvant therapy for biomarker discovery. Multivariate Cox proportional hazard model revealed that paclitaxel‐based chemotherapy was associated with better PFS than nonpaclitaxel chemotherapy (HR = 0.19, P = .006). The addition of bevacizumab was associated with better PFS, compared to no bevacizumab (HR = 0.09, P = .02). Neither showed significant improvement in OS. Recurrence is associated with an Immune‐Hot tumor feature ( P = .03), the CTLA‐4‐high subtype ( P = .01) and increased infiltration of immune cells in general. The Immune‐Hot feature (HR = 3.39, P = .005) and the CTLA‐4‐high subtype (HR = 2.13, P = .059) were associated with worse PFS. Immune‐Hot tumor features could prognosticate recurrence in early‐stage OCCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCarcinomaAdenocarcinoma, Clear CellFemaleHumansCTLA-4 AntigenRetrospective StudiesNeoplasm StagingNeoplasm Recurrence, LocalPrognosis

Stichwörter der Autor:innen

bevacizumabimmune profilingovarian clear cell carcinoma

Substanzen

CTLA-4 Antigen

Autor:innen und Institutionen

  • School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Obstetrics and Gynecology, National Taiwan University Hospital & National Taiwan University College of Medicine, Taipei, Taiwan.
  • National Taiwan University Hospital Yunlin Branch, Douliu City, Taiwan.
  • Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei, Taiwan.
  • Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan, Taiwan.
  • Cancer Science Institute of Singapore, National University of Singapore, Center for Translational Medicine, Singapore.

ORCID-Profile: Kuan-Ju Huang

Zitieren

APA

Huang, R. Y., Huang, K. J., Chen, K. C., Hsiao, S. M., Tan, T. Z., Wu, C. J., Hsu, C., Chang, W. C., Pan, C. Y., Sheu, B. C., & Wei, L. H. (2023). Immune‐Hot tumor features associated with recurrence in early‐stage ovarian clear cell carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.34428

Vancouver

Huang RY, Huang KJ, Chen KC, Hsiao SM, Tan TZ, Wu CJ, et al. Immune‐Hot tumor features associated with recurrence in early‐stage ovarian clear cell carcinoma. International Journal of Cancer. 2023. doi:10.1002/ijc.34428

BibTeX
@article{Huang2023,
  author = {Huang, Ruby Yun-Ju and Huang, Kuan-Ju and Chen, Ko-Chen and Hsiao, Sheng-Mou and Tan, Tuan Zea and Wu, Chin-Jui and Hsu, Ching and Chang, Wen-Chun and Pan, Chen-Yu and Sheu, Bor-Ching and Wei, Lin-Hung},
  title = {Immune‐Hot tumor features associated with recurrence in early‐stage ovarian clear cell carcinoma},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34428}
}
Kostenlos starten →